Management of Cardiovascular Risk Factors
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00848380
First received: February 19, 2009
Last updated: November 15, 2010
Last verified: November 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases. The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia
| Condition |
|---|
|
Cardiovascular Risk Factors Cardiovascular Diseases |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
| Official Title: | Management of Cardiovascular Risk Factors |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- The goal is an evaluation of the development of the risk profile of cardiovascular patients with simultaneous treatment of hypertension and hyperlipidemia. [ Time Frame: Inclusion visit, 6 to 9 months before inclusion visit and / or 12 to 15 months before inclusion visit ] [ Designated as safety issue: No ]
| Enrollment: | 1492 |
| Study Start Date: | February 2009 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Patients with hypertension and hyperlipidemia and other CV risk factors
|
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
Patients with hypertension and hyperlipidemia and other CV risk factors
Criteria
Inclusion Criteria:
- Patients received a anti-hypertension treatment in addition to cholesterol lowering treatment during the observation period
- Patients received a cholesterol lowering treatment in addition to hypertension treatment during the observation period
- Patients received during the observation time new cholesterol lowering and hypertension treatment
Exclusion Criteria:
- Patients received during the observation time only cholesterol lowering or only anti-hypertension treatment
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00848380
Locations
| Switzerland | |
| Research Site | |
| Frick, AG, Switzerland | |
| Research Site | |
| Neuenhof, AG, Switzerland | |
| Research Site | |
| Thun, BE, Switzerland | |
| Research Site | |
| Wynigen, BE, Switzerland | |
| Research Site | |
| Riehen, BS, Switzerland | |
| Research Site | |
| Geneve, GE, Switzerland | |
| Research Site | |
| Le Lignon, GE, Switzerland | |
| Research Site | |
| Meyrin, GE, Switzerland | |
| Research Site | |
| Andeer, GR, Switzerland | |
| Research Site | |
| Ilanz, GR, Switzerland | |
| Research Site | |
| Rorschach, SG, Switzerland | |
| Research Site | |
| St. Gallen, SG, Switzerland | |
| Research Site | |
| Gerlafingen, SO, Switzerland | |
| Research Site | |
| Lohn SO, SO, Switzerland | |
| Research Site | |
| Zuchwil, SO, Switzerland | |
| Research Site | |
| Schwyz, SZ, Switzerland | |
| Research Site | |
| Arbedo, TI, Switzerland | |
| Research Site | |
| Bellinzona, TI, Switzerland | |
| Research Site | |
| Claro, TI, Switzerland | |
| Research Site | |
| Coldrerio, TI, Switzerland | |
| Research Site | |
| Locarno, TI, Switzerland | |
| Research Site | |
| Lugano, TI, Switzerland | |
| Research Site | |
| Muralto, TI, Switzerland | |
| Research Site | |
| Bassins, VD, Switzerland | |
| Research Site | |
| Gland, VD, Switzerland | |
| Research Site | |
| Lausanne, VD, Switzerland | |
| Research Site | |
| Montreux, VD, Switzerland | |
| Research Site | |
| Nyon, VD, Switzerland | |
| Research Site | |
| Zug, ZG, Switzerland | |
| Research Site | |
| Affoltern am Albis, ZH, Switzerland | |
| Research Site | |
| Feldmeilen, ZH, Switzerland | |
| Research Site | |
| Herrliberg, ZH, Switzerland | |
| Research Site | |
| Langnau am Albis, ZH, Switzerland | |
| Research Site | |
| Richterswil, ZH, Switzerland | |
| Research Site | |
| Ruti ZH, ZH, Switzerland | |
| Research Site | |
| Zurich, ZH, Switzerland | |
Sponsors and Collaborators
AstraZeneca
More Information
No publications provided
| Responsible Party: | Dr. Dirk Schneider , Medical Affairs & Regulatory Director, AstraZeneca Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00848380 History of Changes |
| Other Study ID Numbers: | NIS-CCH-DUM-2008/2 |
| Study First Received: | February 19, 2009 |
| Last Updated: | November 15, 2010 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by AstraZeneca:
|
Hypertension hyperlipidemia |
Additional relevant MeSH terms:
|
Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 23, 2013